Elsevier

Human Immunology

Volume 70, Issue 10, October 2009, Pages 809-812
Human Immunology

Clinical manifestation of mannose-binding lectin deficiency in adults independent of concomitant immunodeficiency

https://doi.org/10.1016/j.humimm.2009.07.003Get rights and content

Abstract

Mannose-binding lectin (MBL) mediates important functions within the innate immune system, and its deficiency was associated with infectious complications. However, in adults without concomitant immunodeficiency the clinical relevance of MBL deficiency remains controversial. We analyzed the distribution of MBL deficiency and its association with concomitant immunodeficiency in 228 adult Caucasian patients with a history of recurrent and/or severe infections. Two hundred forty-one unrelated Caucasians without recurrent or severe infections served as control subjects. The frequency of severe MBL deficiency (plasma levels ≤ 50 ng/ml) was significantly higher in patients with a history of recurrent and/or severe infections (p < 0.05, odds ratio 2.1, 95% confidence interval 1.1–4.1), and this association was independent of concomitant antibody or cellular immunodeficiency. Our data challenge the view that MBL deficiency in adulthood becomes relevant only in individuals who are immunocompromised for other reasons.

Introduction

The mannose-binding lectin (MBL) belongs to the family of collectins and is involved in first-line defense against invading microorganisms [1], [2]. Circulating steady-state levels of functional MBL are subject to large interindividual variations, which are mainly determined by genetic polymorphisms within the coding and promoter regions of the MBL2 gene. The correlation between the MBL genotype and phenotype has been well established: (i) normal MBL plasma levels result from the wild-type A/A coding genotype, (ii) partial deficiency is caused by coding mutation heterozygosity (A/0 coding genotype, with “0” being B, C, or D alleles) in combination with certain promoter polymorphisms, and (iii) severe deficiency results from coding mutation homozygosity (O/O genotype) or coding mutation heterozygosity and low promoter haplotypes [1], [3]. The frequencies of the MBL variant alleles differ between ethnic groups and demographic areas [4]. In Caucasians, about 60% of individuals present with the wild-type coding genotype, 30% with coding mutation heterozygosity, and 10% with coding mutation homozygosity [4].

Whereas severe MBL deficiency has been associated with an increased susceptibility to infection in children 6 to 17 months old [5], [6], the clinical impact of MBL deficiency in adults remains controversial [1], [5]. Several studies have indicated that MBL deficiency becomes clinically relevant in adults only in individuals who are immunocompromised for other reasons (e.g., chemotherapy, iatrogenic immunosuppression, surgical stress) [1], [2]. To determine the clinical significance of MBL deficiency and its association with concomitant immunodeficiency in adults, we have analyzed the distribution of MBL deficiency and concomitant antibody or cellular immunodeficiency in a large cohort of unrelated Caucasian adults.

Section snippets

Patients with a history of recurrent and/or severe infections

Two hundred twenty-eight patients with a history of recurrent and/or severe infection (Caucasians, 79.4% female, median age [range]: 40 [16–86] years) were recruited from patients referred to our immunodeficiency outpatient clinics between 2005 and 2008. Patients had been classified as having a history of recurrent and/or severe infections if they had reported four or more infections per year and/or at least one severe infection in the past (e.g., pneumonia). Classification was performed using

Significantly higher prevalence of severe MBL deficiency exists in patients with recurrent and/or severe infections

The distribution of MBL plasma levels in patients with recurrent and/or severe infections and control subjects is illustrated in Fig. 1. The median MBL plasma level over all study participants was 1536.8 (607.5–2665.1) ng/ml, with median values of 1236.8 (468.7–2127.8) ng/ml for patients and 1763.0 (824.1–2873.1) ng/ml for control subjects (p < 0.001 versus patients).

The frequency of individuals with severe MBL deficiency (MBL plasma levels ≤ 50 ng/ml) was significantly higher in patients with

Discussion

In this retrospective study, we reported a significantly increased frequency of severe MBL deficiency in adult patients with a history of recurrent and/or severe infections, and this association persisted even in the absence of concomitant humoral or cellular immunodeficiency. Our data corroborate previous findings indicating a causative link between MBL deficiency and increased susceptibility to infections in adults without suspected other immunodeficiencies [11], [12], [13], [14]. However,

Acknowledgments

The authors thank Sandra Hartfil, Christa Liebenthal, and Claudia Conert for excellent technical assistance, Elizabeth Wallace for accurately proofreading the manuscript, and Wolf-Dietrich Döcke for critically reading the manuscript.

Cited by (19)

  • Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome

    2015, Human Immunology
    Citation Excerpt :

    MBL synthesized in the liver binds to mannose and specific carbohydrates on microbes and is capable of eliminating pathogens directly by opsonophagocytosis and indirectly by complement activation (lectin pathway) [25,26]. MBL deficiency is found at a frequency of 4% in the Caucasian population [27–31]. MBL levels are genetically determined by polymorphism in the mbl2 gene promotor region with allele A for the normal allele, and allele B (GGC to GAC), C (GGA to GAA), and D (CGT to TGT) for MBL amino acid substitutions.

  • Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients

    2013, Transplant Immunology
    Citation Excerpt :

    In 281/321 patients, frequencies of CD3 +, CD4 +, CD8 + and CD31+CD45RA+CD4 + T cells in the peripheral blood were determined between 1 and 6 times (mean 4.2) at days 0, 30, 60, 90, 180 and/or 365 post-Tx by flow cytometry as described previously [16]. In 112/321 patients serum levels of functional MBL were determined between 1 and 3 (mean 1.7) times post-Tx at days 30, 90 and/or 180 using an MBL oligomer enzyme-linked immunosorbent assay kit (Antibody Shop, Gentofte, Denmark) as described elsewhere [25]. Stability of post-Tx MBL values was assessed in 37/112 patients by analysis of a complete series of serum samples at all 3 time points at days 30, 90 and 180 post-Tx.

View all citing articles on Scopus
View full text